VTYX Q1 2025 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$30M

Net Income

-$27M

EPS (Diluted)

$-0.39

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$253M

Total Liabilities

$22M

Stockholders' Equity

$232M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$408,000	+100.0%
Operating Income	-$30M	-$42M	+27.9%
Net Income	-$27M	-$39M	+28.9%